$OPTN
OptiNose, Inc.

2021 Q4 Form 10-K Financial Statement

#000149465022000019 Filed on March 08, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $22.51M $74.65M $16.35M
YoY Change 37.67% 51.99% 47.56%
Cost Of Revenue $2.575M $9.151M $2.240M
YoY Change 14.96% 21.69% 7.69%
Gross Profit $19.93M $65.50M $14.10M
YoY Change 41.38% 57.47% 56.67%
Gross Profit Margin 88.56% 87.74% 86.24%
Selling, General & Admin $26.34M $106.6M $28.11M
YoY Change -6.3% 1.13% 5.88%
% of Gross Profit 132.14% 162.8% 199.36%
Research & Development $5.260M $25.32M $6.450M
YoY Change -18.45% 8.3% 19.89%
% of Gross Profit 26.39% 38.65% 45.74%
Depreciation & Amortization $168.0K $646.0K $420.0K
YoY Change -60.0% -55.63% 82.61%
% of Gross Profit 0.84% 0.99% 2.98%
Operating Expenses $31.60M $132.0M $34.56M
YoY Change -8.56% 2.43% 8.27%
Operating Profit -$11.67M -$66.45M -$20.46M
YoY Change -42.98% -23.81% -10.73%
Interest Expense -$3.966M $15.97M -$3.410M
YoY Change 16.3% 22.79% 64.73%
% of Operating Profit
Other Income/Expense, Net $75.00K $75.00K
YoY Change
Pretax Income -$15.62M -$82.30M -$23.86M
YoY Change -34.52% -17.53% -4.56%
Income Tax
% Of Pretax Income
Net Earnings -$15.62M -$82.30M -$23.86M
YoY Change -34.52% -17.53% -4.56%
Net Earnings / Revenue -69.41% -110.24% -145.93%
Basic Earnings Per Share -$1.45
Diluted Earnings Per Share -$229.9K -$1.45 -$455.7K
COMMON SHARES
Basic Shares Outstanding 82.20M shares 56.85M shares 52.08M shares
Diluted Shares Outstanding 56.85M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.5M $110.5M $144.2M
YoY Change -23.37% -23.37% -1.97%
Cash & Equivalents $110.5M $110.5M $144.2M
Short-Term Investments
Other Short-Term Assets $2.581M $2.581M $4.060M
YoY Change -36.43% -35.48% 7.15%
Inventory $11.85M $11.85M $9.042M
Prepaid Expenses
Receivables $35.45M $35.45M $23.39M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $160.4M $160.4M $180.7M
YoY Change -11.22% -11.25% 7.49%
LONG-TERM ASSETS
Property, Plant & Equipment $1.347M $5.398M $2.028M
YoY Change -33.58% -32.53% -33.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.345M $294.0K $6.133M
YoY Change -29.15% 47.0% 298.76%
Total Long-Term Assets $5.692M $5.692M $8.161M
YoY Change -30.25% -29.73% 77.8%
TOTAL ASSETS
Total Short-Term Assets $160.4M $160.4M $180.7M
Total Long-Term Assets $5.692M $5.692M $8.161M
Total Assets $166.1M $166.1M $188.8M
YoY Change -12.04% -12.04% 9.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.013M $8.013M $5.489M
YoY Change 45.98% 45.69% 51.42%
Accrued Expenses $49.13M $51.22M $44.58M
YoY Change 10.21% 9.68% 42.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $59.24M $59.24M $52.17M
YoY Change 13.54% 13.48% 44.36%
LONG-TERM LIABILITIES
Long-Term Debt $126.4M $126.4M $125.2M
YoY Change 0.97% 0.97% 67.99%
Other Long-Term Liabilities $2.190M $2.190M $4.651M
YoY Change -52.91% -53.4% 1062.75%
Total Long-Term Liabilities $128.6M $128.6M $129.9M
YoY Change -0.96% -0.99% 74.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $59.24M $59.24M $52.17M
Total Long-Term Liabilities $128.6M $128.6M $129.9M
Total Liabilities $187.8M $187.8M $182.0M
YoY Change 3.2% 3.21% 63.89%
SHAREHOLDERS EQUITY
Retained Earnings -$610.1M -$527.8M
YoY Change 15.59% 23.32%
Common Stock $588.4M $534.6M
YoY Change 10.05% 9.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$21.77M -$21.77M $6.788M
YoY Change
Total Liabilities & Shareholders Equity $166.1M $166.1M $188.8M
YoY Change -12.04% -12.04% 9.36%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$15.62M -$82.30M -$23.86M
YoY Change -34.52% -17.53% -4.56%
Depreciation, Depletion And Amortization $168.0K $646.0K $420.0K
YoY Change -60.0% -55.63% 82.61%
Cash From Operating Activities -$16.72M -$76.94M -$19.16M
YoY Change -12.76% -10.75% 5.8%
INVESTING ACTIVITIES
Capital Expenditures -$24.00K $167.0K -$90.00K
YoY Change -73.33% -69.41% 28.57%
Acquisitions
YoY Change
Other Investing Activities $0.00 $105.0K
YoY Change
Cash From Investing Activities -$24.00K -$62.00K -$90.00K
YoY Change -73.33% -88.64% 28.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $43.14M
YoY Change 28.39%
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities 43.01M $43.32M 20.31M
YoY Change 111.76% -48.31% -49.01%
NET CHANGE
Cash From Operating Activities -16.72M -$76.94M -19.16M
Cash From Investing Activities -24.00K -$62.00K -90.00K
Cash From Financing Activities 43.01M $43.32M 20.31M
Net Change In Cash 26.27M -$33.66M 1.060M
YoY Change 2378.21% 1027.39% -95.1%
FREE CASH FLOW
Cash From Operating Activities -$16.72M -$76.94M -$19.16M
Capital Expenditures -$24.00K $167.0K -$90.00K
Free Cash Flow -$16.69M -$77.10M -$19.07M
YoY Change -12.47% -11.12% 5.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001494650
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2019Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38241
CY2021 dei Entity Registrant Name
EntityRegistrantName
OPTINOSE, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
42-1771610
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1020 Stony Hill Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Yardley
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19067
CY2021 dei City Area Code
CityAreaCode
267
CY2021 dei Local Phone Number
LocalPhoneNumber
364-3500
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2021 dei Trading Symbol
TradingSymbol
OPTN
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
94600000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82418106 shares
CY2021Q4 us-gaap Inventory Net
InventoryNet
11847000 USD
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, PA
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
110502000 USD
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
144156000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35449000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23394000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
9042000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2581000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4060000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
160379000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
180652000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1347000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2028000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4345000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6133000 USD
CY2021Q4 us-gaap Assets
Assets
166071000 USD
CY2020Q4 us-gaap Assets
Assets
188813000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8013000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5489000 USD
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
51222000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
46683000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59235000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52172000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
126418000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
125202000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2190000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4651000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
187843000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
182025000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82238900 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82238900 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52945865 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52945865 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
82000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
588288000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
534585000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-610061000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-527765000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-81000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-21772000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6788000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
166071000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
188813000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
74652000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49117000 USD
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9151000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7520000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25318000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23378000 USD
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
106633000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105438000 USD
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
141102000 USD
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
136336000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-66450000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-87219000 USD
CY2021 optn Grant And Other Income
GrantAndOtherIncome
75000 USD
CY2020 optn Grant And Other Income
GrantAndOtherIncome
0 USD
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
52000 USD
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
442000 USD
CY2021 us-gaap Interest Expense
InterestExpense
15973000 USD
CY2020 us-gaap Interest Expense
InterestExpense
13008000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-82296000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-99785000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.07
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.07
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56851921 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56851921 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48275230 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48275230 shares
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-82296000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-99785000 USD
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-37000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82292000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99822000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61583000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10284000 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33401000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
228000 USD
CY2020 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
864000 USD
CY2020 optn Stock Issued During Period Value Debt Issuance
StockIssuedDuringPeriodValueDebtIssuance
250000 USD
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-37000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-99785000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6788000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9977000 USD
CY2021 optn Stock Issued During Period Vested Restricted Stock Units
StockIssuedDuringPeriodVestedRestrictedStockUnits
0 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42814000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
534000 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39000 USD
CY2021 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
368000 USD
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-82296000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-21772000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-82296000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-99785000 USD
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
646000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1456000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
10003000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
10349000 USD
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1795000 USD
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1193000 USD
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-233000 USD
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
677000 USD
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
67000 USD
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11823000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10427000 USD
CY2021 optn Increase Decrease In Grantsand Other Receivables
IncreaseDecreaseInGrantsandOtherReceivables
-43000 USD
CY2020 optn Increase Decrease In Grantsand Other Receivables
IncreaseDecreaseInGrantsandOtherReceivables
-175000 USD
CY2021 optn Increase Decreasein Depositsand Other Assets
IncreaseDecreaseinDepositsandOtherAssets
-3543000 USD
CY2020 optn Increase Decreasein Depositsand Other Assets
IncreaseDecreaseinDepositsandOtherAssets
-1074000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2713000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5428000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2564000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2196000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1603000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12314000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76935000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86206000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
167000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
546000 USD
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
105000 USD
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-546000 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
43140000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33600000 USD
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
54447000 USD
CY2021 optn Proceedsfrom Issuanceof Common Stock Under Employee Stock Purchase Plan
ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan
368000 USD
CY2020 optn Proceedsfrom Issuanceof Common Stock Under Employee Stock Purchase Plan
ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan
865000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
39000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
228000 USD
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
227000 USD
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
883000 USD
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4447000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43320000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83810000 USD
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13000 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-44000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33664000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2986000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144179000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147165000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110515000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144179000 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
14170000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
11561000 USD
CY2021 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
11000 USD
CY2020 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
52000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
534000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 USD
CY2021 us-gaap Stock Issued1
StockIssued1
0 USD
CY2020 us-gaap Stock Issued1
StockIssued1
250000 USD
CY2021 optn Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses
DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses
318000 USD
CY2020 optn Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses
DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses
65000 USD
CY2021 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
157000 USD
CY2020 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
6174000 USD
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
157000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
6174000 USD
CY2021 us-gaap Nature Of Operations
NatureOfOperations
Organization and Description of Business<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OptiNose, Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania, Ewing, New Jersey, and Oslo, Norway. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the Company's proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018.</span></div>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
110502000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div>
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
109017000 USD
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
141944000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
444000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
677000 USD
CY2021 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0 USD
CY2020 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0 USD
CY2021 us-gaap Advertising Expense
AdvertisingExpense
15638000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
15015000 USD
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12418139 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9154679 shares
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3504000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2669000 USD
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4816000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2676000 USD
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3527000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3697000 USD
CY2021Q4 us-gaap Inventory Gross
InventoryGross
11847000 USD
CY2020Q4 us-gaap Inventory Gross
InventoryGross
9042000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5630000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5814000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4283000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3786000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1347000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2028000 USD
CY2021 us-gaap Depreciation
Depreciation
645000 USD
CY2020 us-gaap Depreciation
Depreciation
1454000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2411000 USD
CY2021Q4 optn Operating Lease Right Of Use Asset Noncurrent
OperatingLeaseRightOfUseAssetNoncurrent
4051000 USD
CY2020Q4 optn Operating Lease Right Of Use Asset Noncurrent
OperatingLeaseRightOfUseAssetNoncurrent
5978000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2094000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2108000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2190000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4161000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4284000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6269000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M2D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0455
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2461000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1831000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
424000 USD
CY2021Q4 optn Lessee Operating Lease Liability Payments Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueThereafter
0 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4716000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
432000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4284000 USD
CY2021 optn Operating Lease Cost For Extension
OperatingLeaseCostForExtension
0 USD
CY2021 us-gaap Lease Cost
LeaseCost
2843000 USD
CY2020 us-gaap Lease Cost
LeaseCost
2770000 USD
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2466000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
857000 USD
CY2021Q4 optn Accrued Product Allowances Current
AccruedProductAllowancesCurrent
26521000 USD
CY2020Q4 optn Accrued Product Allowances Current
AccruedProductAllowancesCurrent
20917000 USD
CY2021Q4 optn Accrued Selling Generaland Administrative Current
AccruedSellingGeneralandAdministrativeCurrent
6124000 USD
CY2020Q4 optn Accrued Selling Generaland Administrative Current
AccruedSellingGeneralandAdministrativeCurrent
7385000 USD
CY2021Q4 optn Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
6857000 USD
CY2020Q4 optn Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
5202000 USD
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7569000 USD
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9063000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2057000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2008000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49128000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
44575000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2094000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2108000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2094000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2108000 USD
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
51222000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
46683000 USD
CY2021Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1300000 USD
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1340000 USD
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1466000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
280000 USD
CY2021Q4 us-gaap Purchase Obligation
PurchaseObligation
0 USD
CY2021Q4 optn Vote Per Share
VotePerShare
1 vote
CY2021 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10003000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10349000 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-78801000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-93849000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-3495000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5936000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82296000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-99785000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.004
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2021 optn Effective Income Tax Rate Reconciliation Foreign Operations Impact Percent
EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent
0
CY2020 optn Effective Income Tax Rate Reconciliation Foreign Operations Impact Percent
EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.001
CY2021 optn Effective Income Tax Rate Reconciliation Foreign Exchange Other Percent
EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent
-0.009
CY2020 optn Effective Income Tax Rate Reconciliation Foreign Exchange Other Percent
EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent
-0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.245
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.260
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
6712000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
5062000 USD
CY2021Q4 optn Deferred Tax Assets Prepaid License Arrangement
DeferredTaxAssetsPrepaidLicenseArrangement
9441000 USD
CY2020Q4 optn Deferred Tax Assets Prepaid License Arrangement
DeferredTaxAssetsPrepaidLicenseArrangement
10251000 USD
CY2021Q4 optn Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
10708000 USD
CY2020Q4 optn Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
7141000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
8583000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
6819000 USD
CY2021Q4 optn Deferred Tax Assets Leasing Arrangement
DeferredTaxAssetsLeasingArrangement
1081000 USD
CY2020Q4 optn Deferred Tax Assets Leasing Arrangement
DeferredTaxAssetsLeasingArrangement
1551000 USD
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2461000 USD
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2485000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
87324000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
73278000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
126310000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
106587000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
210000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
220000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1024000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1479000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1234000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1699000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
125076000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
104888000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2487000 USD
CY2021 optn Deferred Tax Assets Tax Credit Carryforwards Research Term
DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm
P20Y
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20188000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD

Files In Submission

Name View Source Status
0001494650-22-000019-index-headers.html Edgar Link pending
0001494650-22-000019-index.html Edgar Link pending
0001494650-22-000019.txt Edgar Link pending
0001494650-22-000019-xbrl.zip Edgar Link pending
amendedandrestatedemployme.htm Edgar Link pending
amendedandrestatedemploymea.htm Edgar Link pending
amendedandrestatedemploymeb.htm Edgar Link pending
amendedandrestatedemploymec.htm Edgar Link pending
amendedandrestatedemploymed.htm Edgar Link pending
auditorconsent10-kex23110k.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
formindemnificationagreeme.htm Edgar Link pending
listofsubsidiariesex21110k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mmarinoretentionagreement3.htm Edgar Link pending
optinoselogorgba31a.jpg Edgar Link pending
optn-20211231.htm Edgar Link pending
optn-20211231.xsd Edgar Link pending
optn-20211231_cal.xml Edgar Link unprocessable
optn-20211231_def.xml Edgar Link unprocessable
optn-20211231_g1.jpg Edgar Link pending
optn-20211231_g2.jpg Edgar Link pending
optn-20211231_g3.jpg Edgar Link pending
optn-20211231_g4.jpg Edgar Link pending
optn-20211231_g5.jpg Edgar Link pending
optn-20211231_g6.jpg Edgar Link pending
optn-20211231_g7.jpg Edgar Link pending
optn-20211231_g8.jpg Edgar Link pending
optn-20211231_g9.jpg Edgar Link pending
optn-20211231_htm.xml Edgar Link completed
optn-20211231_lab.xml Edgar Link unprocessable
optn-20211231_pre.xml Edgar Link unprocessable
optn12-31x202110xkex311.htm Edgar Link pending
optn12-31x202110xkex312.htm Edgar Link pending
optn12-31x202110xkex321.htm Edgar Link pending
optn12-31x202110xkex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending